Nanobiotix Announces Third Quarter 2020 Revenue

Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited revenue for the third quarter of 2020.

Revenue for the Third Quarter of 2020 (unaudited)

In K€	3Q 2020	2Q 2020	1Q 2020	3Q 2019
Revenue	14.7	13.4	23.5	11.1
Of which licenses	-	-	-	-
Of which services	14.7	13.4	23.5	11.1

Revenue for the Nine Months Ended September 30^th, 2020 (unaudited)

In K€	Nine Months Ended September 30, 2020	Nine Months Ended September 30, 2019
Revenue	51.6	48.2
Of which licenses	-	-
Of which services	51.6	48.2

Activity and Results

Nanobiotix’s total revenue for the third quarter of 2020 amounted to €14.7K. Total revenue for the nine months ended September 30, 2020 amounted to €51.6K.

Most of the revenue generated by the Company during this period resulted from the cross-charge to its partner, PharmaEngine, of shared external contract research organization costs pursuant to the license and collaboration agreement.